530 results on '"Introna, Martino"'
Search Results
2. Safety and Preliminary Efficacy of Mesenchymal Stromal Cell (ORBCEL-M) Therapy in Diabetic Kidney Disease: A Randomized Clinical Trial (NEPHSTROM)
3. Safety, tolerability, and activity of mesenchymal stem cells versus placebo in multiple sclerosis (MESEMS): a phase 2, randomised, double-blind crossover trial
4. Third-party bone marrow–derived mesenchymal stromal cell infusion before liver transplantation: A randomized controlled trial
5. Sleeping Beauty-engineered CAR T cells achieve antileukemic activity without severe toxicities
6. Autologous Mesenchymal Stromal Cell Therapy for Idiopathic Nephrotic Syndrome: The MESNEPH Study: PUB225
7. Optimization and validation of in vivo flow cytometry chimeric antigen receptor T cell detection method using CD19his indirect staining.
8. A phase I study of autologous mesenchymal stromal cells for severe steroid-dependent nephrotic syndrome
9. Optimization and validation of in vivo flow cytometry CAR‐T cell detection method using CD19his indirect staining
10. Cord blood–derived cytokine-induced killer cells combined with blinatumomab as a therapeutic strategy for CD19+ tumors
11. Utility of routine evaluation of sterility of cellular therapy products with or without extensive manipulation: Best practices and clinical significance
12. Phase II Study of Sequential Infusion of Donor Lymphocyte Infusion and Cytokine-Induced Killer Cells for Patients Relapsed after Allogeneic Hematopoietic Stem Cell Transplantation
13. Multiple intracerebroventricular injections of human umbilical cord mesenchymal stem cells delay motor neurons loss but not disease progression of SOD1G93A mice
14. Potency assays and biomarkers for cell-based advanced therapy medicinal products
15. Human neutrophils mediate trogocytosis rather than phagocytosis of CLL B cells opsonized with anti-CD20 antibodies
16. Development of advanced therapies in Italy: Management models and sustainability in six Italian cell factories
17. Longitudinal tracking of triple labeled umbilical cord derived mesenchymal stromal cells in a mouse model of Amyotrophic Lateral Sclerosis
18. Immune Reconstitution Following Infusion of Autologous Blinatumomab Expanded T-Cells (BET) in CD20+ Indolent Non-Hodgkin Lymphomas and Chronic Lymphocytic Leukemia Receiving Front-Line Treatment with Fludarabine-Cyclophosphamide-Rituximab or Bendamustine-Rituximab
19. Carcik-CD19 Cells Expand In Vivo Toward a CD8+ Memory Phenotype and Their Persistence Is Associated with a Longer Duration of Response
20. Final Results of Phase I/II Study of Donor-Derived CAR T Cells Engineered with Sleeping Beauty in Pediatric and Adult Patients with B-Cell Acute Lymphoblastic Leukemia Relapsed Post-HSCT
21. Treatment of Graft versus Host Disease with Mesenchymal Stromal Cells: A Phase I Study on 40 Adult and Pediatric Patients
22. Kinetics of the use of cryopreserved autologous stem cell grafts: a GITMO-SIDEM survey
23. Direct involvement of CD56 in cytokine-induced killer–mediated lysis of CD56+ hematopoietic target cells
24. Therapeutic potential of stromal cells of non-renal or renal origin in experimental chronic kidney disease
25. Glycoengineered CD20 antibody obinutuzumab activates neutrophils and mediates phagocytosis through CD16B more efficiently than rituximab
26. A comprehensive report of long-term stability data for a range ATMPs: A need to develop guidelines for safe and harmonized stability studies
27. Immunotherapy for HER2-Positive Breast Cancer: Clinical Evidence and Future Perspectives
28. Optimization of therapeutic T cell expansion in G-Rex device and applicability to large-scale production for clinical use
29. Cytokine Regulation of Endothelial Cell Function
30. Minimally manipulated whole human umbilical cord is a rich source of clinical-grade human mesenchymal stromal cells expanded in human platelet lysate
31. Enhanced killing of human B-cell lymphoma targets by combined use of cytokine-induced killer cell (CIK) cultures and anti-CD20 antibodies
32. Donor-Derived CAR T Cells Engineered with Sleeping Beauty in Pediatric and Adult Patients with Acute Lymphoblastic Leukemia Relapsed Post-HSCT
33. Safety, tolerability, and activity of mesenchymal stem cells versus placebo in multiple sclerosis (MESEMS): a phase 2, randomised, double-blind crossover trial
34. Platelet-lysate-Expanded Mesenchymal Stromal Cells as a Salvage Therapy for Severe Resistant Graft-versus-Host Disease in a Pediatric Population
35. The washouts of discarded bone marrow collection bags and filters are a very abundant source of hMSCs
36. A policy for the disposal of autologous hematopoietic progenitor cells: report from an Italian consensus panel
37. Rituximab induces different but overlapping sets of genes in human B-lymphoma cell lines
38. Tolerance to Bone Marrow Transplantation: Do Mesenchymal Stromal Cells Still Have a Future for Acute or Chronic GvHD?
39. Donor-Derived CAR T Cells Engineered with Sleeping Beauty Achieve Anti-Leukemic Activity without Severe Toxicity
40. Sleeping Beauty–engineered CAR T cells achieve antileukemic activity without severe toxicities
41. Mesenchymal stromal cells and kidney transplantation: pretransplant infusion protects from graft dysfunction while fostering immunoregulation
42. Small Dose of Rituximab for Graves Orbitopathy: New Insights Into the Mechanism of Action
43. Targeting CD33 in Chemoresistant AML Patient-Derived Xenografts by CAR-CIK Cells Modified with an Improved SB Transposon System
44. Protective Effects of Human Nonrenal and Renal Stromal Cells and Their Conditioned Media in a Rat Model of Chronic Kidney Disease
45. Kidney transplant tolerance associated with remote autologous mesenchymal stromal cell administration
46. Donor-Derived CD19 CAR Cytokine Induced Killer (CIK) Cells Engineered with Sleeping Beauty Transposon for Relapsed B-Cell Acute Lymphoblastic Leukemia (B-ALL)
47. MEsenchymal StEm cells for Multiple Sclerosis (MESEMS): a randomized, double blind, cross-over phase I/II clinical trial with autologous mesenchymal stem cells for the therapy of multiple sclerosis
48. Suicide gene therapy and the control of graft-vs-host disease
49. Detection of a transcriptional block in the first intron of the human c-myb gene
50. Acquired immunodeficiency syndrome-associated lymphomas are efficiently lysed through complement-dependent cytotoxicity and antibody-dependent cellular cytotoxicity by rituximab
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.